参考文献/References:
[1] Hubalewska-Daydejczyk A,Trofimiuk M,Sowa-Staszczak A,et al.Somatostatin receptors expression (SSTR1-SSTR5)in pheochromo-cytomas.Przegl Lek,2008,65(9):405-407.
[2] Shen HC,Wang XW,Liu YG.A tumor growth inhibition of paclitaxel-octreotide conjugates on human non small cell lung cancer experiment with mice.Zhonghua Yi Xue Za Zhi,2008,88(35):2498-2503.
[3] Acunzo J,Thirion S,Roche C,et al.Somatostatin receptor sst2 decreases cell viability and hormonal hypersecretion and reverses octreotide resistance of human pituitary adenomas.Cancer Res,2008,68(24):10163-10170.
[4] Krantic S.Peptides as regulators of the immuse system:emphasis on somatostatin.Peptides,2000,21(12):1941-1946.
[5] Kaszper E,Hanzély Z,Szende B,et al.Examination of somatostatin receptor expression in recurrent childhood medulloblastomas.Magy Onkol,2008,52(4):351-355.
[6] Virgolini I,Traub T,Novotny C,et aL Experience with indium-111 and yttrium-90-labeled somatostatin analogs.Curr Pharm Des,2002,8(20):1781-1807.
[7] Elgeti F,Amthauer H,Denecke T,et al.Incidental detection of breast cancer by 68Ga-DOTATOC-PET/CT in women suffering from neuroendocrine tumours.Nuklearmedizin,2008,47(6):261-265.
[8] Kuan CT,Wikstrand CJ,Me Lendon RE,et al.Detection of amino-terminal extracellular domain of somatostatin receptor 2 by specific monoclonal antibodies and quantification of receptor density in medulloblastoma.Hybridoma,2009,28(6):389-403.
[9] Pisarek H,Stepień T,Kubiak R,et al.Somatostatin receptors inhuman adrenal gland tumors-immunohistochemical study.Folia Histochem Cytobiol,2008,46(3):345-351.
[10] Thomson VS,Narayanan K,Singh JC.Contrast induced nephropathy in urology.Indian J Urol,2009,25(4):437-445.
[11] Wild D,Schmitt JS,Cinj M,et al.DOTA-NOC,a high-affinity ligand of somatostatin receptor subtypes 2,3 and 5 for labelling with various radiometals.Eur J Nucl Med Mol Imaging,2003,30(10):1338-1347.
[12] Shah T,Kulakiene I,Quigley AM,et al.The role of 99mTc-depreotide in the management of neuroendocrine tumours.Nucl Medi Commun,2008,29(5):436-440.
[13] Van Den Bossche B,Van Belle S,De Winter F,et al.Early prediction of endocrine therapy effect in advanced breast cancer patients using 99mTc-depreotide scintigraphy.J Nucl Med,2006,47(1):6-13.
[14] Blum J,Nandmaker H,Lister-James J,et al.A multicenter trial with a somatostatin analog 99Tcm depreotide in the evaluation of solitary pulmonary nodules.Chest,2000,117(5):1232-1237.
[15] 王峰,王自正,姚薇萱,等.99Tcm-sandostatin生长抑素受体显像用于诊断肺癌.中华核医学杂志,2004,24(2):104-106.
[16] Schottelius M,Wester HJ,Heubi JC,et al.Improvement of pharmacokinetics of radioiodinated Tyr(3)-octreotide by conjugation with carbohydrates.Bioconjug Chem,2002,13(5):1021-1030.
[17] Lebtahi R,Le Cloirec J,Houzard C,et al.Detection of neuroendocrine tumors:99mTC-P829 scintigraphy compared with 111In-pentetreotide scintigraphy.J Nucl Med,2002,43(7):889-895.
[18] Wester HJ,Schottelius M,Scheidhauer K,et al.PET imaging of somatostatin receptors:design,synthesis and preclinical evaluation of a novel 18F-labelled,carbohydrated analogue of octreotide.Eur J Nucl Med Mol Imaging,2003,30(1):117-122.
[19] Wester HJ,Schottelius M,Scheidhauer K,et al. Comparison of radioiodinated TOC,TOCA and Mtr-TOCA:the effect of carbohydration on the pharmacokinetics.Eur J Nucl Med Mol Imaging,2002,29(1):28-38.
[20] Virgolini I,Britton K,Buscombe J,et al.111In-and 99Y-DOTA-lanreotide:results and implications of the MAURITIUS trial.Semin Nucl Med,2002,32(2):148-155.
[21] Wild D,Häcke HR,Waser B,et al.68Ga-DOTANOC:a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5.Eur J Nucl Med Mol Imaging,2005,32(6):724.
[22] Maggio R,Aloisi G,Silvano E,et al.Heterodimerization of dopamine receptors:new insights into functional and therapeutic significance.Parkinsonism Relat Disord,2009,15(4):S2-S7.
[23] Lee LT,Schally AV,Liebow C,et al.Dephosphorylation of cancer protein by tyrosine phosphatases in response to analogs of luteinizing hormone-releasing hormone and somatostatin.Anticancer Res,2008,28(5A):2599-2605.
[24] Barresi V,Alafaci C,Salpietro F,et al.Sstr2Aimmunohisto-chemical expression in human meningiomas:is there a correlation with the histological grade,proliferation or microvessel density?.Oncol Rep,2008,20(3):485-492.
相似文献/References:
[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]邢宇,赵新明.放射性核素标记HER2亲和体分子探针精准诊疗的研究进展[J].国际放射医学核医学杂志,2016,40(2):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
Xing Yu,Zhao Xinming.Advances in radionuclide-labeled HER2 affibody molecular probes for precise diagnosis and treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
[3]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[4]杨洋,樊赛军.LXXLL模体在雌激素受体信号通路中的作用及应用价值[J].国际放射医学核医学杂志,2014,38(1):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
Yang Yang,Fan Saijun.Role of LXXLL motif in modulation of estrogen receptor signaling and its potential application[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
[5]白庆双,李宁,方佩华,等.人血清TRAb酶联免疫吸附试验检测在甲状腺疾病患者中的临床应用[J].国际放射医学核医学杂志,2014,38(2):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
Bai Qingshuang,Li Ning,Fang Peihua,et al.The clinical application of human serum level of the TRAb measured by enzyme-linked immunosorbent assay in patients with thyroid diseases[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
[6]李丽,赵长久,田国梅.CXC型趋化因子受体4及其分子显像剂在肿瘤方面的研究进展[J].国际放射医学核医学杂志,2014,38(3):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
Li Li,Zhao Changjiu,Tian Guomei.Research progress of CXC chemokine receptor type 4 and molecular imaging in tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
[7]周晓靓,王浩,施培基,等.表皮生长因子受体-酪氨酸激酶肿瘤分子显像剂的研究进展[J].国际放射医学核医学杂志,2013,37(2):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
ZHOU Xiao-liang,WANG Hao,SHI Pei-ji,et al.The developme nt of epidermal growth factor receptor molecular imaging in cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
[8]林美福,陈文新,周硕,等.18F-FES PET/CT显像在雌激素受体阳性乳腺癌诊疗中的初步应用[J].国际放射医学核医学杂志,2013,37(4):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
LIN Mei-fu,CHEN Wen-xin,ZHOU Shuo,et al.Application of 18F-FES PET/CT in diagnosis and endocrine therapy of patients with estrogen receptorpositive breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
[9]袁杰,刘兴党,韩梅.SPECT、PET神经受体和转运体显像技术在海洛因成瘾研究中的应用[J].国际放射医学核医学杂志,2013,37(1):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
YUAN Jie,LIU Xing-dang,HAN Mei.Neuroreceptor and its transporters imaging by PET and SPECT in heroin addiction[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
[10]鲍伟奇,邱春,管一晖.γ-氨基丁酸A型-苯二氮革受体显像剂在神经系统疾病中的应用[J].国际放射医学核医学杂志,2012,36(1):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
BAO Wei-qi,QIU Chun,GUAN Yi-hui.Application of gamma-aminobutyric acid type A-benzodiazepine receptor imaging for study of neuropsychiatric disorders[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(6):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
[11]刘淼,刘兴党.生长抑素受体显像剂99Tcm-奥曲肽的SPECT研究[J].国际放射医学核医学杂志,2012,36(3):138.[doi:10.3760/cma.j.issn.1673-4114.2012.03.003]
LIU Miao,LIU Xing-dang.Development of study on SPECT imaging with radioisotope 99Tcm-octreotide[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(6):138.[doi:10.3760/cma.j.issn.1673-4114.2012.03.003]
[12]夏伟,吕中伟,王国玉,等.99Tcm标记depreotide及与肺腺癌A549细胞亲和性研究[J].国际放射医学核医学杂志,2010,34(4):193.[doi:10.3760/cma.j.issn.1673-4114.2010.04.001]
XIA Wei,LÜ,Zhong-wei,et al.Experimental studies of depreotide labeled with 99Tcm and the affinity with human lung adenocarcinoma cell line A549[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(6):193.[doi:10.3760/cma.j.issn.1673-4114.2010.04.001]
[13]侯仁花,吕中伟.生长抑素受体显像剂99mTc-depreotide的研究进展[J].国际放射医学核医学杂志,2008,32(1):15.
HOU Ren-hua,LÜ,Zhong-wei.The progress of a new somatostatin receptor agent 99mTc-depreotide[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(6):15.
[14]王秀娟,李险峰.生长抑素受体肿瘤显像的临床应用及研究进展[J].国际放射医学核医学杂志,2006,30(4):217.
WANG Xiu-juan,LI Xian-feng.Clinical application and progress of somatostatin receptor imaging in diagnosis of cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(6):217.
[15]郭睿,晋建华.99mTc-depreotide生长抑素受体显像的临床应用研究[J].国际放射医学核医学杂志,2007,31(3):154.
GUO Rui,JIN Jian-hua.The clinical application and study of 99mTc-depreotide somatostatin receptor imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(6):154.
[16]王佳琼,王自正,姚薇萱,等.乳腺肿瘤生长抑素受体表达与生长抑素受体显像[J].国际放射医学核医学杂志,2006,30(1):17.
WANG Jia-qiong,WANG Zi-zheng,YAO Wei-xuan,et al.Somatostatin receptor scintigraphy and somatostatin receptors expression in breast neoplasm[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(6):17.
[17]章斌.188Re直接标记octreotide的方法学[J].国际放射医学核医学杂志,2002,26(5):220.
ZHANG Bin.Investigations of directly labelling octreotide with 188Re[J].International Journal of Radiation Medicine and Nuclear Medicine,2002,26(6):220.